Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy
The authors describe the evidence and results obtained in 21 out of 100 patients who underwent salvage retroperitoneal lymphadenectomy for advanced testicular cancer (UICC stage II/B bulky and stage III) in the period 1982-1993, and in whom inductive chemotherapy was not followed by marker conversio...
Gespeichert in:
| Veröffentlicht in: | International urology and nephrology 1995-05, Vol.27 (3), p.325-329 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 329 |
|---|---|
| container_issue | 3 |
| container_start_page | 325 |
| container_title | International urology and nephrology |
| container_volume | 27 |
| creator | Kisbenedek, L Bodrogi, I Szeldeli, P Baki, M Tenke, P Horti, J |
| description | The authors describe the evidence and results obtained in 21 out of 100 patients who underwent salvage retroperitoneal lymphadenectomy for advanced testicular cancer (UICC stage II/B bulky and stage III) in the period 1982-1993, and in whom inductive chemotherapy was not followed by marker conversion. It is stated that if AFP positivity is low (titres below 100 ng/ml) salvage retroperitoneal lymphadenectomy (RLA) is of high therapeutic value, whereas in all cases with HCG positivity or AFP titres higher than 500 ng/ml tumorous death ensued without exception. In our cases viable tumour residues occurred in 81%. Salvage resection was feasible in 76%, but every incomplete resection (19%) was followed by death due to tumour. In all but one of the cases marker positivity, an indicator of therapy-resistant viable tumour residues, persisted after having used more than four PVB combinations or changes in the chemotherapeutic regimen. |
| doi_str_mv | 10.1007/BF02564770 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77694103</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77694103</sourcerecordid><originalsourceid>FETCH-LOGICAL-c197t-25e3f12dc7488414280345f344eaf3eb274b76481fdb6f29d1f07005ce6f33bf3</originalsourceid><addsrcrecordid>eNpFUcFO3DAUtCoqutBeuCP5hKDSlufYiZMjoFIqrVQJtefISZ53TWM72A7Vfld_EC-s4PTeSKOZN28IOWHwjQHIy-tbKMpKSAkfyIKVki-LshYHZAEc2JJVBf9EjmJ8AICmBjgkh7JsWNnUC_L_HuM8pki9plGNT2qNNGAKfsJgkneoRjpu7bRRAzrsk7dben6_urqgxtG0QZoCqmTRpZ3CpJLJa6T_TNpQ511Ea5y3Kvk50jUGS3scR5pm6-cQs5NVxhm3plaFvxjo5KNJ5gmp0ilD44a5f8H9Bq3PfkFN28_ko1ZjxC_7eUz-3H7_fXO3XP368fPmarXsWSNT_gFyzYqhl6KuBRNFDVyUmguBSnPsCik6WYma6aGrdNEMTIMEKHusNOed5sfk7FV3Cv5xxphaa-LufuUw52mlrBrBgGfi11diH3yMAXU7BZMTbVsG7a6h9r2hTD7dq86dxeGNuq-EPwMYTZB6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77694103</pqid></control><display><type>article</type><title>Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Kisbenedek, L ; Bodrogi, I ; Szeldeli, P ; Baki, M ; Tenke, P ; Horti, J</creator><creatorcontrib>Kisbenedek, L ; Bodrogi, I ; Szeldeli, P ; Baki, M ; Tenke, P ; Horti, J</creatorcontrib><description>The authors describe the evidence and results obtained in 21 out of 100 patients who underwent salvage retroperitoneal lymphadenectomy for advanced testicular cancer (UICC stage II/B bulky and stage III) in the period 1982-1993, and in whom inductive chemotherapy was not followed by marker conversion. It is stated that if AFP positivity is low (titres below 100 ng/ml) salvage retroperitoneal lymphadenectomy (RLA) is of high therapeutic value, whereas in all cases with HCG positivity or AFP titres higher than 500 ng/ml tumorous death ensued without exception. In our cases viable tumour residues occurred in 81%. Salvage resection was feasible in 76%, but every incomplete resection (19%) was followed by death due to tumour. In all but one of the cases marker positivity, an indicator of therapy-resistant viable tumour residues, persisted after having used more than four PVB combinations or changes in the chemotherapeutic regimen.</description><identifier>ISSN: 0301-1623</identifier><identifier>EISSN: 1573-2584</identifier><identifier>DOI: 10.1007/BF02564770</identifier><identifier>PMID: 7591598</identifier><language>eng</language><publisher>Netherlands</publisher><subject>Antineoplastic Agents - therapeutic use ; Biomarkers, Tumor - metabolism ; Combined Modality Therapy ; Follow-Up Studies ; Germinoma - metabolism ; Germinoma - pathology ; Germinoma - therapy ; Humans ; Lymph Node Excision ; Male ; Neoplasm Staging ; Retroperitoneal Space - surgery ; Retrospective Studies ; Salvage Therapy ; Testicular Neoplasms - metabolism ; Testicular Neoplasms - pathology ; Testicular Neoplasms - therapy</subject><ispartof>International urology and nephrology, 1995-05, Vol.27 (3), p.325-329</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c197t-25e3f12dc7488414280345f344eaf3eb274b76481fdb6f29d1f07005ce6f33bf3</citedby><cites>FETCH-LOGICAL-c197t-25e3f12dc7488414280345f344eaf3eb274b76481fdb6f29d1f07005ce6f33bf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7591598$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kisbenedek, L</creatorcontrib><creatorcontrib>Bodrogi, I</creatorcontrib><creatorcontrib>Szeldeli, P</creatorcontrib><creatorcontrib>Baki, M</creatorcontrib><creatorcontrib>Tenke, P</creatorcontrib><creatorcontrib>Horti, J</creatorcontrib><title>Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy</title><title>International urology and nephrology</title><addtitle>Int Urol Nephrol</addtitle><description>The authors describe the evidence and results obtained in 21 out of 100 patients who underwent salvage retroperitoneal lymphadenectomy for advanced testicular cancer (UICC stage II/B bulky and stage III) in the period 1982-1993, and in whom inductive chemotherapy was not followed by marker conversion. It is stated that if AFP positivity is low (titres below 100 ng/ml) salvage retroperitoneal lymphadenectomy (RLA) is of high therapeutic value, whereas in all cases with HCG positivity or AFP titres higher than 500 ng/ml tumorous death ensued without exception. In our cases viable tumour residues occurred in 81%. Salvage resection was feasible in 76%, but every incomplete resection (19%) was followed by death due to tumour. In all but one of the cases marker positivity, an indicator of therapy-resistant viable tumour residues, persisted after having used more than four PVB combinations or changes in the chemotherapeutic regimen.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Combined Modality Therapy</subject><subject>Follow-Up Studies</subject><subject>Germinoma - metabolism</subject><subject>Germinoma - pathology</subject><subject>Germinoma - therapy</subject><subject>Humans</subject><subject>Lymph Node Excision</subject><subject>Male</subject><subject>Neoplasm Staging</subject><subject>Retroperitoneal Space - surgery</subject><subject>Retrospective Studies</subject><subject>Salvage Therapy</subject><subject>Testicular Neoplasms - metabolism</subject><subject>Testicular Neoplasms - pathology</subject><subject>Testicular Neoplasms - therapy</subject><issn>0301-1623</issn><issn>1573-2584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFUcFO3DAUtCoqutBeuCP5hKDSlufYiZMjoFIqrVQJtefISZ53TWM72A7Vfld_EC-s4PTeSKOZN28IOWHwjQHIy-tbKMpKSAkfyIKVki-LshYHZAEc2JJVBf9EjmJ8AICmBjgkh7JsWNnUC_L_HuM8pki9plGNT2qNNGAKfsJgkneoRjpu7bRRAzrsk7dben6_urqgxtG0QZoCqmTRpZ3CpJLJa6T_TNpQ511Ea5y3Kvk50jUGS3scR5pm6-cQs5NVxhm3plaFvxjo5KNJ5gmp0ilD44a5f8H9Bq3PfkFN28_ko1ZjxC_7eUz-3H7_fXO3XP368fPmarXsWSNT_gFyzYqhl6KuBRNFDVyUmguBSnPsCik6WYma6aGrdNEMTIMEKHusNOed5sfk7FV3Cv5xxphaa-LufuUw52mlrBrBgGfi11diH3yMAXU7BZMTbVsG7a6h9r2hTD7dq86dxeGNuq-EPwMYTZB6</recordid><startdate>199505</startdate><enddate>199505</enddate><creator>Kisbenedek, L</creator><creator>Bodrogi, I</creator><creator>Szeldeli, P</creator><creator>Baki, M</creator><creator>Tenke, P</creator><creator>Horti, J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199505</creationdate><title>Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy</title><author>Kisbenedek, L ; Bodrogi, I ; Szeldeli, P ; Baki, M ; Tenke, P ; Horti, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c197t-25e3f12dc7488414280345f344eaf3eb274b76481fdb6f29d1f07005ce6f33bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Combined Modality Therapy</topic><topic>Follow-Up Studies</topic><topic>Germinoma - metabolism</topic><topic>Germinoma - pathology</topic><topic>Germinoma - therapy</topic><topic>Humans</topic><topic>Lymph Node Excision</topic><topic>Male</topic><topic>Neoplasm Staging</topic><topic>Retroperitoneal Space - surgery</topic><topic>Retrospective Studies</topic><topic>Salvage Therapy</topic><topic>Testicular Neoplasms - metabolism</topic><topic>Testicular Neoplasms - pathology</topic><topic>Testicular Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kisbenedek, L</creatorcontrib><creatorcontrib>Bodrogi, I</creatorcontrib><creatorcontrib>Szeldeli, P</creatorcontrib><creatorcontrib>Baki, M</creatorcontrib><creatorcontrib>Tenke, P</creatorcontrib><creatorcontrib>Horti, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International urology and nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kisbenedek, L</au><au>Bodrogi, I</au><au>Szeldeli, P</au><au>Baki, M</au><au>Tenke, P</au><au>Horti, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy</atitle><jtitle>International urology and nephrology</jtitle><addtitle>Int Urol Nephrol</addtitle><date>1995-05</date><risdate>1995</risdate><volume>27</volume><issue>3</issue><spage>325</spage><epage>329</epage><pages>325-329</pages><issn>0301-1623</issn><eissn>1573-2584</eissn><abstract>The authors describe the evidence and results obtained in 21 out of 100 patients who underwent salvage retroperitoneal lymphadenectomy for advanced testicular cancer (UICC stage II/B bulky and stage III) in the period 1982-1993, and in whom inductive chemotherapy was not followed by marker conversion. It is stated that if AFP positivity is low (titres below 100 ng/ml) salvage retroperitoneal lymphadenectomy (RLA) is of high therapeutic value, whereas in all cases with HCG positivity or AFP titres higher than 500 ng/ml tumorous death ensued without exception. In our cases viable tumour residues occurred in 81%. Salvage resection was feasible in 76%, but every incomplete resection (19%) was followed by death due to tumour. In all but one of the cases marker positivity, an indicator of therapy-resistant viable tumour residues, persisted after having used more than four PVB combinations or changes in the chemotherapeutic regimen.</abstract><cop>Netherlands</cop><pmid>7591598</pmid><doi>10.1007/BF02564770</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-1623 |
| ispartof | International urology and nephrology, 1995-05, Vol.27 (3), p.325-329 |
| issn | 0301-1623 1573-2584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77694103 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Antineoplastic Agents - therapeutic use Biomarkers, Tumor - metabolism Combined Modality Therapy Follow-Up Studies Germinoma - metabolism Germinoma - pathology Germinoma - therapy Humans Lymph Node Excision Male Neoplasm Staging Retroperitoneal Space - surgery Retrospective Studies Salvage Therapy Testicular Neoplasms - metabolism Testicular Neoplasms - pathology Testicular Neoplasms - therapy |
| title | Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T12%3A23%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Results%20of%20salvage%20retroperitoneal%20lymphadenectomy%20(RLA)%20in%20the%20treatment%20of%20patients%20with%20nonseminomatous%20germ%20cell%20tumours%20remaining%20marker%20positive%20after%20inductive%20chemotherapy&rft.jtitle=International%20urology%20and%20nephrology&rft.au=Kisbenedek,%20L&rft.date=1995-05&rft.volume=27&rft.issue=3&rft.spage=325&rft.epage=329&rft.pages=325-329&rft.issn=0301-1623&rft.eissn=1573-2584&rft_id=info:doi/10.1007/BF02564770&rft_dat=%3Cproquest_cross%3E77694103%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77694103&rft_id=info:pmid/7591598&rfr_iscdi=true |